ABSTRACT
INTRODUCTION
DNA damage affects carcinogenesis, transcription, alternative splicing, and cell cycle control; however, the precise mechanism behind these affects remains largely unexplored. FUSE-binding protein (FBP) is a transcription factor that stimulates c-myc expression [1] [2] [3] . FBPinteracting repressor (FIR) is a c-myc transcriptional repressor that functions by suppressing the TFIIH/ P89/XPB helicase (P89) [4] [5] [6] [7] ; hence, enhanced FIR showed antitumor effect in mouse xenografted model by suppressing c-myc [8] [9] [10] . Markedly , a splice variant of FIR that lacks exon 2 in the transcriptional repression domain (FIRΔexon2) elevates c-Myc protein expression in vitro [11] . FIRΔexon2 mRNA is frequently upregulated in human colorectal cancers [12] as well as hepatocellular carcinoma [13] , where it stimulates tumor growth by preventing FIR from suppressing c-myc [13] . FIRΔexon2 functions as a dominant negative regulator of FIR; therefore it reduces FIR function. Recent studies suggested that DNA damage induces alternative splicing of several genes including FIR [14, 15] . Specifically, FIR/FIRΔexon2 monitors the DNA damage response by potentially interacting with DNA-PKcs or Ku-86 [14] . Therefore, DNA damage may induce persistent c-myc upregulation via FIRΔexon2 in cancer cells, whereas it induces TP53 in normal cells FIR is a splice variant of PUF60, reported as a splicing factor that lacks the exon 5 consists of 17 amino acids [16] . SAP155, a subunit of the SF3b spliceosome complex, interacts directly with PUF60 in vitro [17] and could be co-immunoprecipitated with FIR (or FIRΔexon2)-FLAG beads in vivo [18] .Furthermore, SAP155 is required for proper FIR pre-mRNA splicing; therefore, SAP155-FIR complex formation inhibits the well-established functions of both SAP155 and FIR, disturbing splicing and the transcriptional suppression of c-myc [18, 19] . Accordingly, the FIR/FIRΔexon2/SAP155 interaction, which affects FIR and p21Kip1 splicing, links the DNA damage response to c-myc regulation [19] . In fact SAP155 mutations, which potentially affect FIR/ FIRΔexon2/SAP155 formation, were reported not only in myeloid lineage tumors but also lymphoid lineage tumors [20] [21] [22] [23] . Consequently, an aberrant FIR/FIRΔexon2/ SAP155 interaction is responsible for cancer development and differentiation and is a potent target for cancer screening and treatment [13, 19] .
The upregulation of c-Myc and Notch1 with TP53 loss-of-function is critical for T-ALL pathogenesis [24] . This mechanism involves the loss of F-box WD repeatcontaining protein 7 (FBW7/FBWX7), which was reported to induce sustained c-Myc and Notch1 expression via a post-transcriptional mechanism, resulting in TP53-deficient T-ALL [25, 26] . FBW7 is required for the polyubiquitination-mediated proteasomal degradation of c-Myc. Accordingly, FBW7 modulates leukemia-initiating cell (LIC) activity by regulating c-Myc stability [25] , and thereby plays a role in the pathogenesis [26] . However, the mechanism of c-Myc upregulation in T-ALL in the absence of TP53, FBW7, or Notch1 mutations is unclear. In this study, the significance of disturbed FIR expression was examined by generating FIR +/− mice to assess the dominant negative effect of FIRΔexon2. This study indicated that the alternative splicing of FIR links the DNA damage response to c-myc regulation and revealed how the alteration of FIR affects c-Myc, Notch1, or TP53 during the pathogenesis of T-ALL in a FIR +/-
TP53
-/-mouse model.
RESULTS

FIR
-/-mice were embryonic lethal at E9. 5 
or earlier
The design of the FIR-targeting vector ( Figure  1A ), as well as the wild-type, targeted, and deleted FIR alleles used to prepare the FIR +/− mice are shown in Figure  S1 . The FIR homozygous knockout mouse FIR −/− was prepared by the cross-fertilization of FIR +/− mice ( Figure   TP53 generates thymic lymphoma, FIR +/-TP53 -/-generated T-cell type acute lymphocytic/ lymphoblastic leukemia (T-ALL) with increased organ or bone marrow invasion with poor prognosis. RNA-sequencing analysis of sorted thymic lymphoma cells revealed that the Notch signaling pathway was activated significantly in FIR +/− TP53 −/− compared with that in FIR +/+ TP53 −/− mice. Notch1 mRNA expression in sorted thymic lymphoma cells was confirmed using qRT-PCR. In addition, flow cytometry revealed that c-myc mRNA was negatively correlated with FIR but positively correlated with Notch1 in sorted T-ALL/ thymic lymphoma cells. Moreover, the knockdown of TP53 or c-myc using siRNA decreased Notch1 expression in cancer cells. In addition, an adenovirus vector encoding FIRΔexon2 cDNA increased bleomycin-induced DNA damage. Taken together, these data suggest that the altered expression of FIRΔexon2 increased Notch1 at least partially by activating c-Myc via a TP53-independent pathway. In conclusion, the alternative splicing of FIR, which generates FIRΔexon2, may contribute to both colorectal carcinogenesis and leukemogenesis. www.impactjournals.com/oncotarget 1B , mouse is embryonic lethal before E9.5, suggesting that FIR is essential for embryogenesis. Proteins expressed during embryogenesis disappear during development but are re-expressed in cancers [27, 28] , suggesting that FIR is crucial for carcinogenesis as well.
FIR
+/− mice exhibited increased c-myc mRNA expression but had no significant deleterious phenotype
The relative expression of c-myc ( Figure 1C ) and FIR ( Figure 1D ) mRNA in the lungs, intestines, heart, kidney, liver, and peripheral blood (PB) of FIR +/− mouse was approximately half of that detected in wild-type mice. However, FIR +/− mouse had no apparent pathogenic phenotype. Recently, five individuals were reported with de novo interstitial 8q24.3 deletions ranging from 65 kb to 1 Mb on the chromosome that includes FIR (PUF60). These deletions had a clinical phenotype that was associated with multiple systemic phenotypes but no hematological malignancy or lymphoma [29, 30] . This suggests that the haploinsufficiency of PUF60 (FIR) with c-myc mRNA elevation alone is not sufficient to drive the pathogenesis of T-ALL.
FIR is alternatively spliced in human leukemia
To explore how c-myc is activated in T-ALL/ lymphoma, the alternative splicing of FIR, the ratio of FIR/FIRΔexon2, and c-myc mRNA expression were examined in human leukemia samples ( Figure 1E , Table  S1 ). qRT-PCR for the cDNA of full-length FIR variants was performed in bone marrow or peripheral blood samples using primers to amplify the amino terminal region. At least four variants (FIR, PUF60, FIRΔexon2, and PUF60Δexon2) were expected from the alternative use of the two potential exons [12] . The ratio of FIR/ FIRΔexon2 mRNA ( Figure 1F 
TP53
−/− mice was performed ( Figure 3C ). These analyses revealed that both 
−/− mice compared with that in control mice ( Figure 3D , gated area). . FIR -/-mouse was revealed to be embryonic lethal at least before E9.5 by cross-fertilized between FIR hetero knockout mouse. The relative expression of c-myc and FIR mRNAs from lung, intestinal mucosae, heart muscle, kidneys, livers and peripheral blood (PB) were examined. (C) c-myc mRNA of PB of FIR hetero knockout mice was three-times higher than those of wild mouse. 
Haploinsufficiency of FIR developed rapid T-ALL progression with bone marrow invasion
TP53
−/− mice with T-ALL/lymphoma exhibited a significantly lower bodyweight than did FIR +/+ ( Figure  4C ). One-hundred percent of wild-type and FIR
mice survived during the study period, and the overall survival rate (Kaplan-Meier) of FIR
-/-mice was better than that of FIR
-/-( Figure 4D ). There were no significant differences in the nose-to-anus length and bodyweight of FIR +/− compared with that of wild-type mice (FIR +/+ ) ( Figure S2 ). These results suggest that FIR haploinsufficiency promoted the progression of T-ALL/ lymphoma, reduced bodyweight, and was associated with a poorer prognosis. The incidence of T-ALL with > 10% bone marrow infiltration of blast cells was higher in FIR 
P53
-/-mice, seven had T-ALL (41.2%), 10 had thymic lymphoma (58.8%), and one exhibited bone marrow invasion (5.9%) ( Figure 4F ). 
Comparison of RNA-sequencing analysis of sorted thymic lymphoma cells from FIR
+
TP53
+/+ mice examined in this study ( Figure S3E ). 
P53
-/-mice was at least partly Notch1 upregulation because c-myc and Notch1 mRNAs were positively correlated (Figures 6C, D) . Together, the current FIR haploinsufficiency mouse model revealed that T-ALL/ lymphoma was generated via a p53-dependent pathway, but that its progression was potentially due to a c-Mycindependent mechanism because the TP53 single knockout alone exhibited sustained c-Myc expression.
Knocking down TP53 and c-myc using siRNA suppressed Notch1 expression Bleomycin (BLM)-induced DNA damage induces FIR splicing [14] . The alternative splicing of FIR contributes to the transcriptional regulation of c-myc, which is critical for cell cycle control. Because Notch1 expression is pivotal for the pathogenesis of T-ALL, TP53 or c-myc were knocked down using siRNA whereas BLM was treated as DNA damaging agent to examine the relationship among DNA damage, the alternative splicing of FIR, and cell cycle control. Knocking down both TP53 and c-myc using siRNA significantly suppressed Notch1 expression without disturbing FIR expression (Figures 7A-C, arrows). TP53 expression was not affected significantly by the enforced expression by FIR//FIRΔexon2 using an adenovirus vector ( Figure 7D ). DNA damage affects the alternative splicing of FIR, which contributes to the transcriptional activation of c-myc via a dominant negative effect on endogenous FIR [14] . Activated c-Myc accelerates the cell cycle by suppressing p27Kip1 expression, which leads to the accumulation of DNA damage [14, 15] .These results suggest that disturbed FIR expression or the altered splicing of FIR may contribute to the pathogenesis of T-ALL via upregulating c-MycNotch1 axis independent on TP53 ( Figure 7E) . Therefore, FIR splicing is a novel mechanism that links DNA damage to c-myc regulation ( Figure 7E ).
DISCUSSION
The conditional FIR +/− mouse exhibited prominent 
TP53
−/− (N166) mice, as revealed by RNA-sequencing analysis ( Figure 5 ). Quantitative RT-PCR confirmed that c-myc mRNA expression was negatively correlated with FIR mRNA expression but positively correlated with Notch1 mRNA in sorted T-ALL/thymic lymphoma cells ( Figure 6 ). Furthermore, knocking down TP53 or c-myc using siRNA suppressed Notch1 expression; however, TP53 expression was not affected significantly by the enforced expression of FIR/ FIRΔexon2 using an adenovirus vector (Figures 7A-D) . Thus, alternative splicing of FIR expression increased Notch1 through c-Myc upregulation independent on TP53-pathway ( Figure 7E ).
DNA damage affects alternative splicing by modulating the elongation activity and/or the phosphorylation status of RNA polymerase II [15, 31] . In addition, BLM-induced DNA damage alters FIR splicing, which contributes to the transcriptional upregulation of c-myc via dominant negative effect on endogenous FIR [12, 13] . c-Myc accelerates the cell cycle by suppressing p27Kip1 expression, eventually leading to the accumulation of DNA damage. Therefore, FIR splicing is a novel mechanism that connects DNA damage to the regulation of c-myc. The sustained c-Myc and Notch1 protein expression level also needs to be regulated by their stability and degradation process. So, how does FIR splicing contribute to these processes that are pivotal for T-ALL pathogenesis? One possibility is that FIR/FIRΔexon2 interferes with FBW7 (F-box WD repeat-containing protein 7). FBW7 is a polyubiquitin ligase that acts on Cdc4 phospho-degron (CPD) consensus sequence (--TP--S/E--)-containing proteins, including c-Myc and Notch1 [32] [33] [34] [35] [36] . Therefore, leukemic cells from FBW7-deficient mice exhibited the marked accumulation of Notch-1 and c-Myc proteins, which led to the development of T-ALL [25] . The WD-like motifs (W425 and D399) in the CPD-binding propeller pocket of FBW7 are positioned close to each other in the 3D structure after protein folding, and they potentially interact with FIR-UHM (LNGRWFAGRKVVA) (unpublished data). Purified FIRΔexon2 exhibited a higher binding affinity for Skp1-FWB7 than did FIR in a HiTrap Ni affinity column [37] , suggesting that FIRΔexon2 may interact with FBW7 (data not shown). Therefore, FIRΔexon2 may sustain c-Myc protein levels post-transcriptionally by inhibiting the FBW7-mediated pathway. This situation is further complicated because the dimerization site of FIR (PUF60), the RRM2 domain, is not affected by the splicing of exon 2 or 5 in terms of FBP/FIR/FIRΔexon2/PUF60/SAP155 interaction [38, 39] . The difference of the FBP/FIR/ FIRΔexon2/PUF60/SAP155 interaction or regulation among organs also needs to be revealed in carcinogenesis in further study.
The KRAS G12D and Notch1 mutations contribute cooperatively to the leukemogenic transformation of normal T-cells in mouse models [40] . Notch1 mutations, which activate c-myc transcription, were identified in > 50% of T-ALL cases [41] [42] [43] , suggesting that upregulation of Notch1 or c-Myc phosphorylation occurred via the EGFR/KRAS/MEK/ERK pathway [37] . How does the splicing of FIR affect Notch1 or c-Myc phosphorylation? Phosphorylated-ERK (p-ERK) is a substrate of protein phosphatase 1 (PP1). Both Ad-FIR and Ad-FIRΔexon2 activated p-ERK but did not affect PP1 in Jurkat and HeLa cells (data not shown). Ad-FIRΔexon2, but not Ad-FIR, elevated pSer62-c-Myc expression much more than expected by c-myc mRNA level in HeLa cells [16] . Therefore, FIRΔexon2 sustains c-Myc activation via both transcriptional and post-transcriptional mechanisms. Notably, FLAG-tagged FIR or FIRΔexon2 were coimmunoprecipitated with TOPOII-alpha, SAP155, TRRAP, and filamine-A in pull-down assays [14, 18, 19] ; these proteins contain the GKKRVRWADLE sequence, which is specific for interactions with PP1 [44] . Because PP1 inhibits the RAS/BRAF/MEK/ERK pathway [45] and also regulates c-Myc phosphorylation at Ser-62 (pSer62-c-Myc) [46] , FIRΔexon2 may interfere with the function of PP1. However, further studies are required to reveal the detailed mechanism behind this potential effect.
Finally, five individuals had de novo interstitial 8q24.3 (chr8: 144,868,670-144,933,911; USCS Genome Browser hg19, http://genome.ucsc.edu.) deletions ranging from 65 kb to 1 Mb on the chromosome that encodes Scrib [scribbled homologue (MIM 607733)], FIR (PUF60), and NRBP2 (nuclear receptor binding protein 2) [29] . Patients with 8q24.3 deletions showed clinical phenotypes associated with coloboma, congenital heart defects, limb abnormalities, psychomotor retardation, and convulsions; however, no hematologic malignancies or lymphoma have been described [30] . Detecting FIR/FIRΔexon2 for diagnosis, or the use of specific antibodies against FIRΔexon2 or chemicals that inhibit the FIR/FIRΔexon2/ SAP155 interaction may have clinical applications in T-ALL.
Together, these data suggest that the alternative splicing of FIR may link DNA damage to c-myc regulation. Haploinsufficiency of the c-myc transcriptional www.impactjournals.com/oncotarget repressor FIR and the FIR +/−
−/− genotype in mice potently promoted the progression of T-ALL/lymphoma, at least in part by activating the Notch signaling pathway with c-myc/c-Myc upergulation. The alternative splicing of FIR contributes to not only colorectal carcinogenesis but also leukemogenesis.
MATERIALS AND METHODS
Human leukemia samples
Human leukemia, control or adult healthy volunteer samples were obtained from Chiba University Hospital (adult patients) with written informed consent ( Table S1 ).
Generation of animals and ethical approval
C57BL/6NCrSlc mice were obtained from Japan SLC. Mice were bred and maintained in the animal research facility of the Graduate School of Medicine, Chiba University (Chiba, Japan) in accordance with institutional guidelines. This study was approved by the institutional review committees of Chiba University. All experiments using mice received approval from the Chiba University Administrative Panel for Animal Care.
Littermates were used as controls in all experiments. (Figures 1 and S1 ).
Constructing the FIR-targeting vector
Construct of FIR targeting vector was indicated
Homologous recombination of the FIR-targeting vector in ES cells
First, FIR targeting vector was injected by electroporation for homologous recombination ES cells into (C57BL/6) to prepare genetically modified ES cells (C57BL/6). 23 (clone nos. 26, 29, 31, 45, 84, 105, 112, 114, 117, 125, 145, 146, 172, 176, 178, 179, 185, 188, 191, 238, 244, 245 , and 265) of 279 clones were identified in which the FIR-targeting vector had integrated in the chromosomes of ES cells using PCR ( Figure S5A ). The LoxP site of the integrated FIR-targeting vector was confirmed using PCR with suitable primers ( Figure S5B ). The integration of the FIR-targeted allele into the genome was confirmed using Southern blotting with 5′ and 3′ probes ( Figure S5C ). The FIR genomic sequence located between the loxP sites was excised using Cre-recombinase ( Figure S5D ). After verifying that the ES cells had integrated the FIR-targeting allele successfully using PCR and Southern blotting, the ES cells were microinjected into blastocysts from BALB/c mice. The resulting blastocysts were inoculated into the uterus of ICR mice (Table S2) . Male FIR fl/+ chimeric mice (chimera mouse) were crossfertilized with C57BL/6 female mice to obtain F1 FIR heterozygous mice.
Generating inducible FIR heterozygous knockout mice, FIR
+/−
ES cells were purchased from DS Pharma Biomedical Co., Ltd. (Osaka, Japan). The FIR-targeting vector was prepared from Bac clone using PCR, and the FIR heterozygous knockout mice were prepared using the Cre-loxP system in C57BL6 mice [47] (Unitech Co., Ltd, Chiba, Japan) ( Figure S1B ). The primers and probes used to prepare FIR heterozygous knockout mice are shown in Figure 1A and Table S2 . To assess the function of FIR in hematopoiesis, FIR was deleted conditionally by crossing FIR fl/+ mice with CAG-Cre transgenic mice, which express Cre ubiquitously (FIR +/− ) ( Figure S3 ). The efficient deletion of FIR in fetal cells from FIR +/− mice was confirmed using genomic PCR ( Figure 1 , primers loxP_F1, forward; and loxP_R2; reverse; Figure S6 ). The number of chimeric mice, born from clone number 26, 105 and 145 were indicated (Table S2) . Genetically modified ES cells (C57BL/6) were microinjected into the blastocysts of BALB/c mice. Among the 23 positive clones that contained the FIR-targeting vector, clones 26, 105, and 145 ( Figure S6C ) were microinjected into the blastocyst cavity of BALB/c mice and were then transplanted into the uterus of pseudo-pregnant ICR mice. Seven chimeric mice were obtained successfully ( Figure  S6A and Table S2 ). Cross-fertilization was performed between male FIR fl/+ (C57BL/6) and female C57BL/6 mouse to obtain the sperm carrying the FIR fl/+ genome ( Figure S6B ). Finally, FIR fl/+ mice were cross-fertilized with CAG-Cre transgenic mice to obtain FIR fl/+ /Cre(+), which were conditionally inducible FIR heterozygous knockout (FIR +/− ) mice ( Figure S6C ). FIR heterozygous knockout mice were confirmed using the Cre-LoxP system ( Figure S6D ).
Southern blotting of genomic DNA
Three probes were prepared and used for Southern blotting. The 5′-probe (new probe) was located upstream of the short arm in the neomycin gene, and the 3′-probe was located downstream of the long arm ( Figure S1 ). The primers and qRT-PCR conditions used for Southern blotting are shown in Table S5A . 
Registration of FIR heterozygous knockout mice [FIR
TP53-null mice; TP53
−/−
The p53-null mice (TP53 −/− ) were purchased from RIKEN BRC (Bio-Resource Center, Tsukuba, Japan; BRC_No 01361, strain name C57BL-p53+/-).
CAG-Cre-transgenic mice
These mice were a gift from Dr T. Miki [47] .
Measuring the bodyweight and survival curves of mice
The bodyweight of all mice was measured twice a week after the age of 7 weeks. The nose-to-anus length was also measured ( Figure S2 ).
Immunocytochemistry
Cancer cells were prepared for immunocytochemistry as described previously [8] .
Flow cytometry and cell sorting
The antibodies used for immunostaining and flow cytometry are listed in Table S6 . Flow cytometry and cell sorting were performed as described previously [48, 49] . Briefly, linage surface marker antibodies for thymocytes, splenocytes, peripheral blood cells, and bone marrow were Gr-1 (Ly-G6, bone-marrow derived cells), Mac-1 (CD11b, granulocyte, macrophage, etc), B220, CD4 (helper/ induced T cell marker), CD8α (cytotoxic T cell marker), CD45.2 (Leukocyte common antigen). Dead cells were eliminated by staining with propidium iodide (1 μg/mL; Sigma-Aldrich). After cell surface staining, intracellular staining was performed using a FITC-conjugated anti-cMyc antibody. Intraprep TM (Beckman Coulter) was used for fixation and permeabilization. All flow cytometric analyses and cell sorting were performed on FACSAria II or FACSCanto II (BD Biosciences) and analyzed using FACSDiva software (BD Biosciences) and Flowjo (Tree Star, Ashland, OR, USA). siRNA c-myc and TP53 siRNA duplexes were purchased from Sigma-Aldrich (Tokyo, Japan). The transient transfection of siRNAs was performed using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. The transfected cells were cultured for 48-72h at 37°C in a CO 2 incubator. The target sequences for the siRNAs are listed in Supplementary  Table 4 .
Bleomycin treatment
The DNA-damaging agent bleomycin was purchased from Sigma-Aldrich (sulfate powder from Streptomyces verticillus; Tokyo, Japan; Lot no.BCBG6499V; PCode, 101203713), dissolved in distilled H 2 O at a concentration of 5 mg/mL, and stored at −20°C. HLF cells were seeded in 6-well plates and incubated at 37°C/5% CO 2 until confluent (approximately 24 h). Immediately before drug treatment, the media were removed and replaced with fresh culture media. Cells were treated with 30 μg/mL bleomycin alone or co-treated with adenovirus vectors.
Quantitative real-time PCR (qRT-PCR)
Total RNA was isolated using TRIzol LS solution (Invitrogen) and reverse-transcribed using the ThermoScript RT-PCR system (Invitrogen) with oligodT primers. qRT-PCR was performed using an ABI Prism 7300 Thermal Cycler (Applied Biosystems) with FastStart Universal Probe Master (Roche) and Universal Probe Library (Roche). Primers and probes for mouse were listed (Table S5B) .
FIR and FIRΔexon2 adenovirus vectors
FIR and FIRΔexon2 adenovirus vectors were prepared as described previously [18] .
Protein extraction and western blotting
Culture media were removed and the cells were washed twice with cold (4°C) PBS, lysed with 1:20 β-mercaptoethanol and 2x sample buffer, and incubated at 100°C for 5 min. Whole cell lysates were assayed for protein content (Bio-Rad, Hercules, CA, USA), and 10 μg protein samples were separated using SDS-PAGE on 7.5% and 10%-20% XV PANTERA gels. They were then transferred to polyvinylidene fluoride membranes using a tank transfer apparatus, and the membranes were blocked with 0.5% skimmed milk in PBS overnight at 4°C. Membranes were incubated with primary antibodies for 1 h at room temperature, followed by three 10-min washes with PBS/0.01% Tween 20. Membranes were then incubated with secondary antibodies, followed by three 15-min washes with PBS/0.01% Tween 20. Details of the antibodies used in this study are listed in Table S6 . Antigens on the membranes were detected using enhanced chemiluminescence detection reagents (GE Healthcare UK Ltd., Buckinghamshire, UK). 
RNA-sequencing
TP53
−/− mice using TRIzol. The RNA quality was analyzed using a 2100 Bioanalyzer system (Agilent, Santa Clara, CA) to confirm that their RINs (RNA integrity numbers) were > 7.0. RNA-seq was performed to analyze genome-wide gene expression levels. Specifically, RNA-seq libraries were prepared using a TruSeqStranded mRNA LT Sample Prep Kit (Illumina, San Diego, CA) followed by sequencing using a HiSeq1500 genome sequencer 
−/− mice, and the top 100 upregulated genes (Table S2C) were analyzed using KEGG (Kyoto Encyclopedia of Genes and Genomes) software (http:// www.genome.jp/kegg/). Signaling pathways with a FDR (false discovery rate) < 1.0 were selected as significantly activated pathways.
Statistical analysis
The expression of SAP155 and FIR was compared in the lungs, intestine, heart, kidney, and liver of FIR heterozygous knockout adult mice and 14-day-old fetal mice (E14) using Student's t-tests and the Wilcoxon test. The WBC, RBC, and platelet counts, organs' weight curve, and the ratio of FIRΔexon2/FIR mRNA were analyzed statistically using Student's t-tests. Overall survival curves were generated using the Kaplan-Meier method and analyzed statistically using log-rank tests. Statistical analyses were performed using GraphPad Prism version 6.0 for Windows (GraphPad Software, San Diego, CA, USA).
Accession number and genetic information of FIR genome
Ensemble NM_014281.
Conflicts of interest
We have no potential conflicts of interest to disclose.
